


RCF
12.06.05
Filed

12.06.05
12.06.05
12.06.05



AN E.1

OK to
Enter

12/15/05

UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/691,528
Applicant : Wilhelm et al
Filed : October 24, 2003
TC/A.U. : 1623
Examiner : Matthew L. Fedowitz

Docket No. : 2923-576
Customer No. : 6449
Confirmation No. : 7396

Response

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 6, 2005

Dear Sir:

In the Office Action dated June 6, 2005, claims 1-17, in the above-identified U.S. patent application were rejected under 35 USC §103(a). Reconsideration of this rejection is respectfully requested in view of the above amendments and the following remarks. Claims 1-17 remain in this application.

Claims 1-17 were rejected under 35 USC §103(a) as unpatentable over Pentapharm product catalog, Xing, De Vita and Medenica. The Office Action contends that the language "synthetic inhibitor of urokinase" mentioned in the Pentapharm Catalog is a pharmacologic classification of Na(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonyl-piperazine (WX-UK1) not a research chemical classification. Applicants respectfully disagree. The adjective "synthetic" only describes a feature of the inhibitor, i.e. that the inhibitor is available by chemical synthesis in contrast to the natural urokinase inhibitors like PAI-1 and PAI-2 which